## UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

IN RE: PROTON-PUMP INHIBITOR PRODUCTS LIABILITY LITIGATION

2:17-MD-2789 (CCC)(MF) (MDL 2789) and all member and related cases

This Document Relates to: ALL ACTIONS

Judge Claire C. Cecchi

CASE MANAGEMENT ORDER NO. 10 ON MARCH 5, 2018 STATUS CONFERENCE

The Court having held a telephonic case management conference on March 5, 2018, and after reviewing the parties' submissions and having discussed various case management issues with the parties, enters the following ORDER:

- 1. By March 20, 2018, the AstraZeneca Defendants shall provide the PSC with a list of search terms they agree to. Additionally, for any search terms they object to, they will provide the PSC with analytics for those terms consistent with paragraph 4 of CMO No. 8, and any proposed modifications to those terms.
- 2. By April 5, 2018, the Procter & Gamble Defendants shall produce the full and complete IND and NDA for Prilosec OTC.
- 3. By March 19, 2018, the Procter & Gamble Defendants shall produce its clinical study reports for Prilosec OTC. The Procter & Gamble 30(b)(6) deposition on clinical trials shall take place within 7 days from the date of the production of the clinical study reports.
- 4. The 30(b)(6) deposition for the Procter & Gamble Defendants' marketing witness shall be completed by April 13, 2018.
  - 5. The Court has scheduled a telephonic status conference for April 10, 2018 at

11 a.m. The parties shall submit a joint status report and agenda for that conference by April 6, 2018.

6. The Court has scheduled an in-person status conference for May 1, 2018 at 11 a.m. The parties shall submit a joint status report and agenda for that conference by April 27, 2018.

SO ORDERED:

Dated: Newark, New Jersey March (6), 2018

CLAIRE C. CECCHI United States District Judge